Valneva SEINRLF 60 PB Ratio is 5.14 as of Jul. 02, 2026, which is 70% above its 10-year median of 3.03. GuruFocus rates INRLF with a GF Score™ of 60/100 and a GF Value™ of $2.84 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,230 Biotechnology companies, Valneva SE ranks worse than 70% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-02), Valneva SE's share price is $2.62. Valneva SE's Book Value per Share for the quarter that ended in Mar. 2026 was $0.51. Hence, Valneva SE's PB Ratio of today is 5.14.
The historical rank and industry rank for Valneva SE's PB Ratio or its related term are showing as below:
INRLF'
s PB Ratio Range Over the Past 10 Years
Min: 1.37 Med: 3.03 Max: 26.16
Current: 5.1
During the past 13 years, Valneva SE's highest PB Ratio was 26.16. The lowest was 1.37. And the median was 3.03.
INRLF's PB Ratio is ranked worse than 70% of 1230
companies
in the Biotechnology industry
Industry Median: 2.95
vs INRLF: 5.10
During the past 12 months, Valneva SE's average Book Value Per Share Growth Rate was -59.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -27.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -9.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -6.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Valneva SE was 52.50% per year. The lowest was -27.20% per year. And the median was 1.15% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Valneva SE PB Ratio Related Terms
Valneva SE PB Ratio Historical Data
* Premium members only.
The historical data trend for Valneva SE's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Valneva SE's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valneva SE PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valneva SE's PB Ratio distribution charts can be found below:
* The bar in red indicates where Valneva SE's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Valneva SE's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Valneva SE (INRLF) has a PB Ratio of 5.14 as of Jul. 02, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Valneva SE and its competitors. This is 70% above median its historical median of 3.03. Over the past decade, Valneva SE's PB Ratio has ranged from 1.37 to 26.16. According to the industry distribution chart, Valneva SE ranks #861 out of 1230 companies in the Biotechnology industry, placing it in the top 70%.
Is Valneva SE's PB Ratio too high?
Valneva SE's current PB Ratio of 5.14 is 70% above median its 10-year median of 3.03. Over the past 10 years, this metric has ranged from a low of 1.37 to a high of 26.16. The Biotechnology industry median PB Ratio is 2.95. Valneva SE's value of 5.14 is 74.2% above this industry median. Based on the distribution chart, Valneva SE ranks #861 out of 1230 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Valneva SE has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Valneva SE's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Valneva SE ranks #861 out of 1230 companies for PB Ratio. This places Valneva SE in the lower half of its industry. The industry median PB Ratio is 2.95. Valneva SE's value of 5.14 is 74.2% above this benchmark. Historically, Valneva SE's own PB Ratio has ranged from 1.37 to 26.16 over the past decade. While the company's 10-year median is 3.03 vs. the industry median of 2.95, Valneva SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,230 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valneva SE's current PB Ratio of 5.14 is 74.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Valneva SE and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valneva SE's current PB Ratio is 5.14, which is 70% above median its own 10-year median of 3.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valneva SE stock overvalued right now?
Based on GuruFocus' analysis, Valneva SE (INRLF) is currently considered Fairly Valued. The stock's GF Value™ is $2.84, compared to a current price of $2.62 — trading 7.7% below its estimated fair value. The current PB Ratio is 5.14, which is 70% above median its 10-year median of 3.03 and 74.2% above the Biotechnology industry median of 2.95. Valneva SE's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Valneva SE (INRLF), the current PB Ratio is 5.14 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valneva SE (INRLF) Overvalued in 2026?
Based on GuruFocus' analysis, Valneva SE stock appears to be undervalued.
The current stock price of $2.62 is trading 7.7% below its estimated GF Value™ of $2.84.
GuruFocus considers Valneva SE to be Fairly Valued.
Key valuation signals for INRLF:
PB Ratio: 5.14 (70% above median its 10-year median of 3.03)
GF Value™: $2.84 vs. price of $2.62 (7.7% below fair value)
Industry Position: 74.2% above the Biotechnology median (#861 of 1230)
No single metric tells the full story. See the INRLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
60GF Score
Get the complete analysis for INRLF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INRLF has been successfully added to your 
